Literature DB >> 33978830

Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[18F]FDG PET/CT.

Caixia Wu1, Yonggang Cui1, Jumei Liu2, Linlin Ma1, Yan Xiong2, Yanqing Gong3, Yanyan Zhao1, Xi Zhang1, Silu Chen1, Qun He3, Jianhua Zhang1, Meng Liu4, Yan Fan5.   

Abstract

PURPOSE: Nowadays, it is necessary to explore effective biomarkers associated with tumor immune microenvironment (TIME) noninvasively. Here, we investigated whether the metabolic parameter from preoperative 2-[18F]FDG PET/CT could provide information related to TIME in patients with clear cell renal cell carcinoma (ccRCC).
METHODS: Ninety patients with newly diagnosed ccRCC who underwent 2-[18F]FDG PET/CT prior to surgery were retrospectively reviewed. The immunological features included tumor-infiltrating lymphocytes (TILs) density, programmed death-ligand 1 (PD-L1) expression, and tumor immune microenvironment types (TIMTs). TIMTs were classified as TIMT I (positive PD-L1 and high TILs), TIMT II (negative PD-L1 and low TILs), TIMT III (positive PD-L1 and low TILs), and TIMT IV (negative PD-L1 and high TILs). The relationship between maximum standardized uptake value (SUVmax) in the primary lesion from 2-[18F]FDG PET/CT and immunological features was analyzed. Cox proportional hazards analyses were performed to identify the prognostic factors for disease-free survival (DFS) after nephrectomy.
RESULTS: Tumors with high TILs infiltration showed remarkable correlation with elevated SUVmax and aggressive clinicopathological characteristics, such as high World Health Organization/International Society of Urological Pathology (WHO/ISUP) grade. PD-L1 expression on tumor cells was positively associated with WHO/ISUP grade and negatively correlated with body mass index (BMI). However, no correlation was observed between SUVmax and PD-L1 expression, regardless of its spatial tissue distribution. SUVmax of TIMT I and IV was higher than that of TIMT II, but there was remarkable difference merely between TIMT II and IV. In multivariate analysis, SUVmax (P = 0.022, HR 3.120, 95% CI 1.175-8.284) and WHO/ISUP grade (P = 0.046, HR 2.613, 95% CI 1.017-6.710) were the significant prognostic factors for DFS. Six cases (16.2%) with normal SUVmax showed disease progression, while 25 cases (71.4%) with elevated SUVmax experienced disease progression. Conversely, the immunological features held no prognostic value.
CONCLUSIONS: Our findings demonstrated that 2-[18F]FDG PET/CT could provide metabolic information of TIME for ccRCC patients and develop image-guided therapeutic strategies accordingly. Patients with elevated preoperative SUVmax should be seriously considered, and perioperative immunotherapy might be beneficial for them.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Clear cell renal cell carcinoma (ccRCC); Maximum standardized uptake value (SUVmax); Programmed death-ligand 1 (PD-L1); Tumor immune microenvironment (TIME); Tumor immune microenvironment type (TIMT); Tumor-infiltrating lymphocytes (TILs)

Mesh:

Substances:

Year:  2021        PMID: 33978830     DOI: 10.1007/s00259-021-05399-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  36 in total

Review 1.  Classifying Cancers Based on T-cell Infiltration and PD-L1.

Authors:  Michele W L Teng; Shin Foong Ngiow; Antoni Ribas; Mark J Smyth
Journal:  Cancer Res       Date:  2015-06-01       Impact factor: 12.701

2.  PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.

Authors:  Taisuke Yagi; Yoshifumi Baba; Takatsugu Ishimoto; Masaaki Iwatsuki; Yuji Miyamoto; Naoya Yoshida; Masayuki Watanabe; Hideo Baba
Journal:  Ann Surg       Date:  2019-03       Impact factor: 12.969

Review 3.  Cancer Cells Don't Live Alone: Metabolic Communication within Tumor Microenvironments.

Authors:  Fuming Li; M Celeste Simon
Journal:  Dev Cell       Date:  2020-07-07       Impact factor: 12.270

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

5.  Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.

Authors:  Janis M Taube; Robert A Anders; Geoffrey D Young; Haiying Xu; Rajni Sharma; Tracee L McMiller; Shuming Chen; Alison P Klein; Drew M Pardoll; Suzanne L Topalian; Lieping Chen
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

6.  TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.

Authors:  Tsuyoshi Hamada; Thing Rinda Soong; Yohei Masugi; Keisuke Kosumi; Jonathan A Nowak; Annacarolina da Silva; Xinmeng Jasmine Mu; Tyler S Twombly; Hideo Koh; Juhong Yang; Mingyang Song; Li Liu; Mancang Gu; Yan Shi; Katsuhiko Nosho; Teppei Morikawa; Kentaro Inamura; Sachet A Shukla; Catherine J Wu; Levi A Garraway; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Andrew T Chan; Jonathan N Glickman; Scott J Rodig; Gordon J Freeman; Charles S Fuchs; Reiko Nishihara; Marios Giannakis; Shuji Ogino
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

7.  Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration.

Authors:  Chan-Young Ock; Bhumsuk Keam; Sehui Kim; Ju-Seog Lee; Miso Kim; Tae Min Kim; Yoon Kyung Jeon; Dong-Wan Kim; Doo Hyun Chung; Dae Seog Heo
Journal:  Clin Cancer Res       Date:  2016-01-27       Impact factor: 12.531

Review 8.  Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism.

Authors:  Ilaria Elia; Marcia C Haigis
Journal:  Nat Metab       Date:  2021-01-04

Review 9.  Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.

Authors:  Jason Zhu; Andrew J Armstrong; Terence W Friedlander; Won Kim; Sumanta K Pal; Daniel J George; Tian Zhang
Journal:  J Immunother Cancer       Date:  2018-01-25       Impact factor: 13.751

10.  The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.

Authors:  Lu Chen; Mian-Fu Cao; Xiang Zhang; Wei-Qi Dang; Jing-Fang Xiao; Qing Liu; Yu-Huan Tan; Yao-Yao Tan; Yuan-Yuan Xu; Sen-Lin Xu; Xiao-Hong Yao; You-Hong Cui; Xia Zhang; Xiu-Wu Bian
Journal:  Cancer Med       Date:  2019-10-11       Impact factor: 4.452

View more
  1 in total

1.  A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study.

Authors:  Haipeng Tong; Jinju Sun; Jingqin Fang; Mi Zhang; Huan Liu; Renxiang Xia; Weicheng Zhou; Kaijun Liu; Xiao Chen
Journal:  Front Immunol       Date:  2022-04-29       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.